NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis → A.I. is a Tidal Wave - Here’s What to Buy (From Chaikin Analytics) (Ad) Free ALKS Stock Alerts $24.01 -0.53 (-2.16%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$23.26▼$24.2850-Day Range$23.76▼$30.2452-Week Range$22.01▼$33.71Volume2.84 million shsAverage Volume1.90 million shsMarket Capitalization$4.06 billionP/E Ratio11.60Dividend YieldN/APrice Target$35.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Alkermes alerts: Email Address Alkermes MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside47.3% Upside$35.38 Price TargetShort InterestHealthy7.99% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews Sentiment1.10Based on 15 Articles This WeekInsider TradingSelling Shares$292,718 Sold Last QuarterProj. Earnings Growth-9.46%From $2.22 to $2.01 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.90 out of 5 starsMedical Sector24th out of 927 stocksPharmaceutical Preparations Industry7th out of 415 stocks 4.3 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageAlkermes has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.99% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Alkermes has recently decreased by 5.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.17. Previous Next 2.8 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Alkermes this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $292,718.00 in company stock.Percentage Held by InsidersOnly 4.76% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to decrease by -9.46% in the coming year, from $2.22 to $2.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 11.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 11.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 261.43.Price to Earnings Growth RatioAlkermes has a PEG Ratio of 0.69. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & Company#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. For the full story, click here. About Alkermes Stock (NASDAQ:ALKS)Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More ALKS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALKS Stock News HeadlinesMay 1, 2024 | investorplace.comALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024May 1, 2024 | markets.businessinsider.comAlkermes plc Q1 Earnings SummaryMay 2, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 1, 2024 | prnewswire.comAlkermes plc Reports First Quarter 2024 Financial ResultsApril 30, 2024 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) Short Interest UpdateApril 30, 2024 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 30, 2024 | benzinga.comAlkermes Stock (NASDAQ:ALKS), Quotes and News SummaryApril 29, 2024 | americanbankingnews.comAlkermes (ALKS) Set to Announce Quarterly Earnings on WednesdayMay 2, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 24, 2024 | finance.yahoo.comAlkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1April 17, 2024 | prnewswire.comAlkermes to Report First Quarter Financial Results on May 1, 2024April 17, 2024 | finance.yahoo.comAlkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseApril 12, 2024 | markets.businessinsider.comHold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory ChallengesApril 11, 2024 | investing.comJefferies raises Alkermes stock target on positive OX2 dataApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth PotentialApril 9, 2024 | markets.businessinsider.comBreaking Down Alkermes: 5 Analysts Share Their ViewsApril 9, 2024 | msn.comAlkermes posts early-stage win for sleeping disorder therapy (update)April 9, 2024 | seekingalpha.comAlkermes: Waking Up Narcolepsy Treatment With Promising Trial DataApril 9, 2024 | msn.comAlkermes succeeds in early-stage trial for sleeping disorder therapyApril 9, 2024 | seekingalpha.comAlkermes plc: Collecting The Fruits Of The 2023 SpinoffApril 9, 2024 | prnewswire.comAlkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaApril 8, 2024 | prnewswire.comAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research SocietyMarch 29, 2024 | finance.yahoo.comInvestors in Alkermes (NASDAQ:ALKS) have seen favorable returns of 44% over the past three yearsMarch 28, 2024 | nasdaq.comNoteworthy Tuesday Option Activity: ALKS, DKNG, VRTMarch 20, 2024 | investing.comAlkermes exec sells over $290k in company sharesMarch 19, 2024 | msn.comBaird starts Alkermes at outperform, citing revenue streamMarch 19, 2024 | markets.businessinsider.comThe Analyst Verdict: Alkermes In The Eyes Of 4 ExpertsSee More Headlines Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today5/01/2024Next Earnings (Confirmed)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,100Year Founded1987Price Target and Rating Average Stock Price Target$35.38 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+47.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$2.07 Trailing P/E Ratio11.60 Forward P/E Ratio10.82 P/E Growth0.69Net Income$355.76 million Net Margins21.39% Pretax Margin25.34% Return on Equity16.10% Return on Assets9.15% Debt Debt-to-Equity Ratio0.24 Current Ratio2.86 Quick Ratio2.50 Sales & Book Value Annual Sales$1.66 billion Price / Sales2.44 Cash Flow$2.19 per share Price / Cash Flow10.96 Book Value$7.21 per share Price / Book3.33Miscellaneous Outstanding Shares169,180,000Free Float161,131,000Market Cap$4.06 billion OptionableOptionable Beta0.55 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Richard F. Pops (Age 62)Chairman & CEO Comp: $2.61MMr. Blair C. Jackson (Age 51)Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO Comp: $1.17MMr. David Joseph Gaffin (Age 52)Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Comp: $1.15MMr. Iain Michael Brown (Age 55)Senior VP & CFO (Leave of Absence) Comp: $950.88kDr. Craig C. Hopkinson M.D. (Age 56)Executive VP of Research & Development and Chief Medical Officer Comp: $1.24MDr. Floyd E. Bloom M.D. (Age 87)Founder Comp: $57.73kMr. Samuel J. Parisi (Age 49)Interim Principal Accounting Officer & VP of Finance Mr. Thomas HarveyChief Information Officer & Senior VP of ITMs. Sandra CoombsSenior Vice President of Corporate Affairs & Investor RelationsMr. Stephen SchiavoSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLEidos TherapeuticsNASDAQ:EIDXAmicus TherapeuticsNASDAQ:FOLDIonis PharmaceuticalsNASDAQ:IONSGeronNASDAQ:GERNView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsSold 14,958 shares on 5/1/2024Ownership: 0.135%Mirae Asset Global Investments Co. Ltd.Sold 6,111 shares on 5/1/2024Ownership: 0.050%Capstone Investment Advisors LLCBought 32,630 shares on 5/1/2024Ownership: 0.019%Janney Montgomery Scott LLCSold 3,039 shares on 5/1/2024Ownership: 0.018%China Universal Asset Management Co. Ltd.Bought 12,804 shares on 4/29/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions ALKS Stock Analysis - Frequently Asked Questions Should I buy or sell Alkermes stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALKS shares. View ALKS analyst ratings or view top-rated stocks. What is Alkermes' stock price target for 2024? 10 analysts have issued 12 month price targets for Alkermes' shares. Their ALKS share price targets range from $25.00 to $50.00. On average, they expect the company's stock price to reach $35.38 in the next twelve months. This suggests a possible upside of 47.3% from the stock's current price. View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts. How have ALKS shares performed in 2024? Alkermes' stock was trading at $27.74 at the beginning of 2024. Since then, ALKS stock has decreased by 13.4% and is now trading at $24.01. View the best growth stocks for 2024 here. Are investors shorting Alkermes? Alkermes saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 13,520,000 shares, a decrease of 5.7% from the March 31st total of 14,340,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the days-to-cover ratio is currently 6.9 days. View Alkermes' Short Interest. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) announced its earnings results on Wednesday, May, 1st. The company reported $0.43 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.59 by $0.16. The firm earned $350.37 million during the quarter, compared to analysts' expectations of $360.26 million. Alkermes had a trailing twelve-month return on equity of 16.10% and a net margin of 21.39%. The company's quarterly revenue was up 21.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.10) EPS. What ETFs hold Alkermes' stock? ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include Subversive Mental Health ETF (SANE), AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), Invesco S&P SmallCap Health Care ETF (PSCH), Horizon Kinetics Medical ETF (MEDX), First Trust NYSE Arca Biotechnology Index Fund (FBT), ALPS Medical Breakthroughs ETF (SBIO) and Pacer US Small Cap Cash Cows 100 ETF (CALF). How will Alkermes' stock buyback program work? Alkermes declared that its Board of Directors has authorized a stock repurchase plan on Thursday, February 15th 2024, which allows the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 8.2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board believes its stock is undervalued. What guidance has Alkermes issued on next quarter's earnings? Alkermes issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of 2.800-2.800 for the period, compared to the consensus EPS estimate of 2.740. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA). Who are Alkermes' major shareholders? Alkermes' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Principal Financial Group Inc. (0.58%), Rice Hall James & Associates LLC (0.24%), BNP Paribas Financial Markets (0.14%), Los Angeles Capital Management LLC (0.09%), Allspring Global Investments Holdings LLC (0.07%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Alkermes have any subsidiaries? The following companies are subsidiares of Alkermes: Rodin Therapeutics.Read More This page (NASDAQ:ALKS) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingForget Nvidia. This is the future of AIPorter & CompanyAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
